Healthcare & Life Sciences
conoGenetix GmbH
Germany
About
conoGenetix GmbH develops peptide therapeutics that selectively inhibit parts of the immune system responsible for autoimmune diseases such as multiple sclerosis, arthritis, and rheumatism while preserving other immune functions.
Explore conoGenetix GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.